Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05137314 · ClinicalTrials.gov registry record · Phase 1

Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)

A Phase 1 study of Joint Infection, sponsored by Peptilogics.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
12
Study locations

NCT05137314 is a Phase 1 study of Joint Infection that has completed, run by Peptilogics. The registered enrollment target is 14 participants, below the 417-participant average among 6 other Joint Infection trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05137314, a Phase 1 study of Joint Infection, has completed, sponsored by Peptilogics.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .

Conditions Studied

Joint Infection

Interventions

  • DRUG PLG0206

Study Locations (12)

Ohio

  • Cleveland Clinic - Cleveland
  • Ohio State University - Columbus

Texas

  • Memorial Hermann Hospital - Houston
  • Michael E. DeBakey VA Medical Center - Houston

California

  • Stanford Hospital - Palo Alto

Florida

  • Gulfcoast Research - Sarasota

Maryland

  • LifeBridge - Baltimore

Massachusetts

  • Brigham & Women's Hospital - Boston

New York

  • NYU Langone Orthopedic Hospital - New York

Pennsylvania

  • Rothman - Philadelphia

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2022-03-31
Est. Completion 2024-03-19
Phase Phase 1

Sponsor

Peptilogics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05137314

The ClinicalTrials.gov registry entry for NCT05137314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 417-participant average among 6 other Joint Infection trials with a reported enrollment target (97% lower). The listed sponsor is Peptilogics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Joint Infection appearing as the primary indexed condition, and to 1 intervention - of which PLG0206 is the first listed.

NCT05137314 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Ohio, Texas, California.

Frequently Asked Questions

What is clinical trial NCT05137314 about?

NCT05137314 is a clinical study titled "Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)". The purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee a...

What is the current status of trial NCT05137314?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-03-31. Estimated completion is 2024-03-19.

What conditions does trial NCT05137314 study?

This clinical trial studies the following conditions: Joint Infection.

What interventions are being tested in trial NCT05137314?

The interventions under investigation include: PLG0206 (DRUG).

Who is sponsoring clinical trial NCT05137314?

This trial is sponsored by Peptilogics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05137314 being conducted?

This trial has 12 study locations across California, Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Joint Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Joint Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.